Targeting mutations alone may not be enough to control myelodysplastic syndromes (MDS). Experts debated whether disease progression is driven by clonal mutations or the bone marrow microenvironment — and concluded it's likely both. While targeted therapies against specific mutations show promise, the bone marrow niche also plays a critical role in enabling clonal expansion, pointing to a dual-strategy approach for effective disease control.
When it comes to myelodysplastic syndromes (MDS), a key debate is unfolding in hematology: does disease progression come down to the mutations themselves, or does the bone marrow microenvironment (the "niche") call the shots? At the Annual Meeting of the German-Speaking Societies for Hematology and Medical Oncology, two experts squared off — and the answer turned out to be: you need both.
On the clone side, MDS-triggering mutations like SRSF2, IDH, and TP53 often arise surprisingly early — sometimes before birth — and carry varying levels of progression risk. Targeted therapies like enasidenib (for IDH2) and ivosidenib (for IDH1) have shown strong clinical responses, underscoring the importance of mutation-driven treatment strategies. On the niche side, aging-related changes — including chronic inflammation and sympathetic denervation — appear to create a hostile environment for normal stem cells while favoring mutated ones.
Key Takeaways
Why it matters: MDS remains difficult to manage, and this debate highlights that a one-size-fits-all approach won't cut it. Combining mutation-targeted therapies with niche-modifying strategies could represent the next frontier in MDS treatment.
